Testosterone, SHBG and cardiovascular health in postmenopausal women

International Journal of Impotence Research

Volumn 22, Issue 2, 2010, Pages 91-104

  Brand, J S ^a   Van Der Schouw, Y T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GLUCOSE; INSULIN; METFORMIN; METHYLTESTOSTERONE; NANDROLONE DECANOATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY COMPOSITION; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; GLUCOSE METABOLISM; HORMONAL THERAPY; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; INSULIN METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RATING SCALE; REVIEW; RISK FACTOR; WAIST CIRCUMFERENCE;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INSULIN; LIPIDS; POSTMENOPAUSE; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; WAIST CIRCUMFERENCE; WAIST-HIP RATIO;

EID: 77949656152     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/ijir.2009.64     Document Type: Review

References (141)

1. Stampfer MJ, Colditz GA, Willett WC. Menopause and heart disease. A review. Ann N Y Acad Sci 1990; 592: 193-203.
2. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet 1998; 351: 1425-1427.
3. Gorodeski GI. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol 1994; 29: 357-375.
4. Kuller LH, Gutai JP, Meilahn E, Matthews KA, Plantinga P. Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women. Arteriosclerosis 1990; 10: 1058-1066.
5. Lambrinoudaki I, Christodoulakos G, Rizos D, Economou E, Argeitis J, Vlachou S et al. Endogenous sex hormones and risk factors for atherosclerosis in healthy Greek postmenopausal women. Eur J Endocrinol 2006; 154: 907-916.
6. Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab 2005; 90: 1202-1209.
7. Rexrode KM, Manson JE, Lee IM, Ridker PM, Sluss PM, Cook NR et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003; 108: 1688-1693.
8. Barrett-Connor E, Goodman-Gruen D. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women. BMJ 1995; 311: 1193-1196.
9. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann N Y Acad Sci 1990; 592: 263-271.
10. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-529.
11. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49-57.
12. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432-2440.
13. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990; 54: 255-259.
14. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995; 15: 821-826.
15. Maturana MA, Breda V, Lhullier F, Spritzer PM. Relationship between endogenous testosterone and cardiovascular risk in early postmenopausal women. Metabolism 2008; 57: 961-965.
16. Golden SH, Dobs AS, Vaidya D, Szklo M, Gapstur S, Kopp P et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 1289-1295.
17. Haffner SM, Newcomb PA, Marcus PM, Klein BE, Klein R. Relation of sex hormones and dehydroepiandrosterone sulfate (DHEA-SO4) to cardiovascular risk factors in postmenopausal women. Am J Epidemiol 1995; 142: 925-934.
18. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W et al. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006; 91: 3697-3710.
19. Bernini GP, Moretti A, Sgro M, Argenio GF, Barlascini CO, Cristofani R et al. Influence of endogenous androgens on carotid wall in postmenopausal women. Menopause 2001; 8: 43-50.
20. Debing E, Peeters E, Duquet W, Poppe K, Velkeniers B, Van den Brande P. Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy. Eur J Endocrinol 2007; 156: 687-693.
21. Vermeulen A. Plasma androgens in women. J Reprod Med 1998; 43: 725-733.
22. Adashi EY. The climacteric ovary as a functional gonadotropin- driven androgen-producing gland. Fertil Steril 1994; 62: 20-27.
23. Vermeulen A. The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab 1976; 42: 247-253.
24. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-598.
25. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80: 1429-1430.
26. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-3853.
27. Sowers MF, Zheng H, McConnell D, Nan B, Karvonen- Gutierrez CA, Randolph Jr JF. Testosterone, sex hormonebinding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod 2009; 24: 2276-2285.
28. Hammes A, Andreassen TK, Spoelgen R, Raila J, Hubner N, Schulz H et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122: 751-762.
29. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol Biol 1999; 69: 481-485.
30. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982; 16: 801-810.
31. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672.
32. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007; 92: 405-413.
33. Baglietto L, English DR, Hopper JL, MacInnis RJ, Morris HA, Tilley WD et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009; 115: 171-179.
34. Stork S, Bots ML, Grobbee DE, van der Schouw YT. Endogenous sex hormones and C-reactive protein in healthy postmenopausal women. J Intern Med 2008; 264: 245-253.
35. Bezemer ID, Rinaldi S, Dossus L, Gils CH, Peeters PH, Noord PA et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005; 16: 561-572.
36. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S et al. Body mass index, circulating levels of sexsteroid hormones, IGF-I and IGF-binding protein-3: a crosssectional study in healthy women. Eur J Endocrinol 2004; 150: 161-171.
37. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003; 95: 1218-1226.
38. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007; 50: 2076-2084.
39. Phillips GB, Jing T, Heymsfield SB. Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in women. Metabolism 2008; 57: 838-844.
40. Phillips GB, Tuck CH, Jing TY, Boden-Albala B, Lin IF, Dahodwala N et al. Association of hyperandrogenemia and hyperestrogenemia with type 2 diabetes in Hispanic postmenopausal women. Diabetes Care 2000; 23: 74-79.
41. Turcato E, Zamboni M, De Pergola G, Armellini F, Zivelonghi A, Bergamo-Andreis IA et al. Interrelationships between weight loss, body fat distribution and sex hormones in pre- and postmenopausal obese women. J Intern Med 1997; 241: 363-372.
42. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 2003; 88: 1646-1652.
43. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55-60.
44. Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women. Int J Epidemiol 1991; 20: 151-156.
45. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar- Rahmani Y, Modugno F et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 2006; 14: 1662-1677.
46. Lee CC, Kasa-Vubu JZ, Supiano MA. Androgenicity and obesity are independently associated with insulin sensitivity in postmenopausal women. Metabolism 2004; 53: 507-512.
47. Hajamor S, Despres JP, Couillard C, Lemieux S, Tremblay A, Prud'homme D et al. Relationship between sex hormonebinding globulin levels and features of the metabolic syndrome. Metabolism 2003; 52: 724-730.
48. Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. The Rancho Bernardo Study. Diabetes Care 1997; 20: 645-649.
49. Haffner SM, Katz MS, Dunn JF. Increased upper body and overall adiposity is associated with decreased sex hormone binding globulin in postmenopausal women. Int J Obes 1991; 15: 471-478.
50. Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994; 17: 405-411.
51. Preziosi P, Barrett-Connor E, Papoz L, Roger M, Saint-Paul M, Nahoul K et al. Interrelation between plasma sex hormonebinding globulin and plasma insulin in healthy adult women: the telecom study. J Clin Endocrinol Metab 1993; 76: 283-287.
52. Soler JT, Folsom AR, Kaye SA, Prineas RJ. Associations of abdominal adiposity, fasting insulin, sex hormone binding globulin, and estrone with lipids and lipoproteins in postmenopausal women. Atherosclerosis 1989; 79: 21-27.
53. Yasui T, Tomita J, Miyatani Y, Yamada M, Uemura H, Irahara M et al. Associations of adiponectin with sex hormonebinding globulin levels in aging male and female populations. Clin Chim Acta 2007; 386: 69-75.
54. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009; 361: 1152-1163.
55. Svendsen OL, Hassager C, Christiansen C. Relationships and independence of body composition, sex hormones, fat distribution and other cardiovascular risk factors in overweight postmenopausal women. Int J Obes Relat Metab Disord 1993; 17: 459-463.
56. Haffner SM, Dunn JF, Katz MS. Relationship of sex hormonebinding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women. Metabolism 1992; 41: 278-284.
57. Larsson H, Ahren B. Androgen activity as a risk factor for impaired glucose tolerance in postmenopausal women. Diabetes Care 1996; 19: 1399-1403.
58. Phillips GB, Jing TY, Laragh JH. Serum sex hormone levels in postmenopausal women with hypertension. J Hum Hypertens 1997; 11: 523-526.
59. Khaw KT, Barrett-Connor E. Fasting plasma glucose levels and endogenous androgens in non-diabetic postmenopausal women. Clin Sci (Lond) 1991; 80: 199-203.
60. Yasui T, Uemura H, Irahara M, Arai M, Kojimahara N, Okabe R et al. Associations of endogenous sex hormones and sex hormone-binding globulin with lipid profiles in aged Japanese men and women. Clin Chim Acta 2008; 398: 43-47.
61. Page-Wilson G, Goulart AC, Rexrode KM. Interrelation between sex hormones and plasma sex hormone-binding globulin and hemoglobin A1c in healthy postmenopausal women. Metab Syndr Relat Disord 2009; 7: 249-254.
62. Korytkowski MT, Krug EI, Daly MA, Deriso L, Wilson JW, Winters SJ. Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes? Metabolism 2005; 54: 1626-1631.
63. Cauley JA, Gutai JP, Kuller LH, Powell JG. The relation of endogenous sex steroid hormone concentrations to serum lipid and lipoprotein levels in postmenopausal women. Am J Epidemiol 1990; 132: 884-894.
64. Bell RJ, Davison SL, Papalia MA, McKenzie DP, Davis SR. Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause 2007; 14: 630-638.
65. Noyan V, Yucel A, Sagsoz N. The association of androgenic sex steroids with serum lipid levels in postmenopausal women. Acta Obstet Gynecol Scand 2004; 83: 487-490.
66. Folsom AR, Golden SH, Boland LL, Szklo M. Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women. Eur J Epidemiol 2005; 20: 1015-1022.
67. Joffe HV, Ridker PM, Manson JE, Cook NR, Buring JE, Rexrode KM. Sex hormone-binding globulin and serum testosterone are inversely associated with C-reactive protein levels in postmenopausal women at high risk for cardiovascular disease. Ann Epidemiol 2006; 16: 105-112.
68. Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996; 143: 159-166.
69. Crandall C, Palla S, Reboussin B, Hu P, Barrett-Connor E, Reuben D et al. Cross-sectional association between markers of inflammation and serum sex steroid levels in the postmenopausal estrogen/progestin interventions trial. J Womens Health 2006; 15: 14-23.
70. Ouyang P, Vaidya D, Dobs A, Golden SH, Szklo M, Heckbert SR et al. Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2009; 204: 255-261.
71. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632-3639.
72. Braunstein GD, Johnson BD, Stanczyk FZ, Bittner V, Berga SL, Shaw L et al. Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease. J Clin Endocrinol Metab 2008; 93: 4268-4275.
73. Price JF, Lee AJ, Fowkes FG. Steroid sex hormones and peripheral arterial disease in the Edinburgh Artery Study. Steroids 1997; 62: 789-794.
74. Golden SH, Maguire A, Ding J, Crouse JR, Cauley JA, Zacur H et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 2002; 155: 437-445.
75. Phillips GB, Pinkernell BH, Jing TY. Relationship between serum sex hormones and coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17: 695-701.
76. Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L et al. Prehypertension and cardiovascular disease risk in the Women's Health Initiative. Circulation 2007; 115: 855-860.
77. Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation 2005; 111: 1883-1890.
78. Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity 2009; e-pub ahead of print 20 August 2009; doi:10.1038/oby.2009.251.
79. Moran LJ, Noakes M, Clifton PM, Wittert GA, Belobrajdic DP, Norman RJ. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92: 2944-2951.
80. McTiernan A, Tworoger SS, Rajan KB, Yasui Y, Sorenson B, Ulrich CM et al. Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev 2004; 13: 1099-1105.
81. Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity-a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004; 183: 331-342.
82. Corbould AM, Bawden MJ, Lavranos TC, Rodgers RJ, Judd SJ. The effect of obesity on the ratio of type 3 17betahydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intraabdominal adipose tissue of women. Int J Obes Relat Metab Disord 2002; 26: 165-175.
83. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol 2003; 58: 562-571.
84. Elbers JM, Asscheman H, Seidell JC, Gooren LJ. Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999; 276: E317-E325.
85. Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab 1997; 82: 2044-2047.
86. Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women-a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2198-2203.
87. Adams MR, Williams JK, Kaplan JR. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 1995; 15: 562-570.
88. Guthrie JR, Dennerstein L, Taffe JR, Ebeling PR, Randolph JF, Burger HG et al. Central abdominal fat and endogenous hormones during the menopausal transition. Fertil Steril 2003; 79: 1335-1340.
89. Zang H, Ryden M, Wahlen K, Dahlman-Wright K, Arner P, Linden Hirschberg A. Effects of testosterone and estrogen treatment on lipolysis signaling pathways in subcutaneous adipose tissue of postmenopausal women. Fertil Steril 2007; 88: 100-106.
90. Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension 1992; 19: 456-463.
91. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest 1989; 83: 1941-1945.
92. Perez-Torres I, El Hafidi M, Infante O, Banos G. Effects of sex hormone levels on aortic vascular reactivity and variables associated with the metabolic syndrome in sucrose-fed female rats. Can J Physiol Pharmacol 2008; 86: 25-35.
93. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 1998; 83: 4420-4425.
94. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79: 265-271.
95. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab 2002; 87: 2870-2874.
96. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996; 81: 952-960.
97. Holmang A, Larsson BM, Brzezinska Z, Bjorntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992; 262: E851-E855.
98. Rincon J, Holmang A, Wahlstrom EO, Lonnroth P, Bjorntorp P, Zierath JR et al. Mechanisms behind insulin resistance in rat skeletal muscle after oophorectomy and additional testosterone treatment. Diabetes 1996; 45: 615-621.
99. Plymate SR, Jones RE, Matej LA, Friedl KE. Regulation of sex hormone binding globulin (SHBG) production in Hep G2 cells by insulin. Steroids 1988; 52: 339-340.
100. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62: 904-910.
101. Adashi EY, Hsueh AJ, Yen SS. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 1981; 108: 1441-1449.
102. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075-4079.
103. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Bjorntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991; 40: 123-128.
104. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga- Thie GM, Fauser BC, Westerveld EH et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008; 93: 470-476.
105. Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril 2009; 92: 626-634.
106. Desmeules A, Couillard C, Tchernof A, Bergeron J, Rankinen T, Leon AS et al. Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: The HERITAGE Family Study. Atherosclerosis 2003; 171: 343-350.
107. Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X. Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 2002; 43: 1163-1169.
108. Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 2002; 80: 753-769.
109. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
110. Montalcini T, Gorgone G, Gazzaruso C, Sesti G, Perticone F, Pujia A. Endogenous testosterone and endothelial function in postmenopausal women. Coron Artery Dis 2007; 18: 9-13.
111. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 5088-5095.
112. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007; 22: 3197-3203.
113. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C et al. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17: 2192-2199.
114. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 1999; 99: 2317-2322.
115. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation 1995; 91: 1154-1160.
116. Cooper BC, Gokina NI, Osol G. Testosterone replacement increases vasodilatory reserve in androgen-deficient female rats. Fertil Steril 2007; 87: 422-425.
117. Haffner SM, Moss SE, Klein BE, Klein R. Sex hormones and DHEA-SO4 in relation to ischemic heart disease mortality in diabetic subjects. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 1996; 19: 1045-1050.
118. Lapidus L, Lindstedt G, Lundberg PA, Bengtsson C, Gredmark T. Concentrations of sex-hormone binding globulin and corticosteroid binding globulin in serum in relation to cardiovascular risk factors and to 12-year incidence of cardiovascular disease and overall mortality in postmenopausal women. Clin Chem 1986; 32: 146-152.
119. Goodman-Gruen D, Barrett-Connor E. A prospective study of sex hormone-binding globulin and fatal cardiovascular disease in Rancho Bernardo men and women. J Clin Endocrinol Metab 1996; 81: 2999-3003.
120. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006; 13: 770-779.
121. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-688.
122. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995; 21: 227-236.
123. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005; 105: 944-952.
124. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165: 1582-1589.
125. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226-5233.
126. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006; 13: 387-396.
127. Nathorst-Boos J, Floter A, Jarkander-Rolff M, Carlstrom K, Schoultz B. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido-effects on sexuality and psychological general well-being. Maturitas 2006; 53: 11-18.
128. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J 1987; 294: 936-937.
129. Farish E, Fletcher CD, Hart DM, Azzawi FA, Abdalla HI, Gray CE. The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women. Acta Endocrinol 1984; 106: 116-120.
130. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993; 82: 919-924.
131. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995; 85: 529-537.
132. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol 2002; 57: 209-214.
133. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 1509-1516.
134. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003; 79: 1341-1352.
135. Warnock JK, Swanson SG, Borel RW, Zipfel LM, Brennan JJ. Combined esterified estrogens and methyltestosterone versus esterified estrogens alone in the treatment of loss of sexual interest in surgically menopausal women. Menopause 2005; 12: 374-384.
136. Leao LM, Duarte MP, Silva DM, Bahia PR, Coeli CM, de Farias ML. Influence of methyltestosterone postmenopausal therapy on plasma lipids, inflammatory factors, glucose metabolism and visceral fat: a randomized study. Eur J Endocrinol 2006; 154: 131-139.
137. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999; 44: 1012-1020.
138. Raisz LG,Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. J Clin Endocrinol Metab 1996; 81: 37-43.
139. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L et al. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril 2001; 76: 235-240.
140. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med 2008; 359: 2005-2017.
141. Hak AE, Westendorp IC, Pols HA, Hofman A, Witteman JC. High-dose testosterone is associated with atherosclerosis in postmenopausal women. Maturitas 2007; 56: 153-160.